Abstract
Clinical manifestations of tumors indicate that malignant phenotypes develo** in the hypoxic microenvironment lead to resistance to cancer treatment, rendering chemotherapy, radiotherapy, and photodynamic therapy less sensitive and effective in patients with tumor. Visualizing the oxygen level in the tumor environment has garnered much attention due to its implications in precision tumor therapy. Following the rapid development of biomaterials in nanotechnology, various nanomaterials have been designed to visualize the oxygen levels in tumors. Here, we review recent research on detecting oxygen levels in solid tumors for tumor hypoxia imaging. To monitor the hypoxic level of tumors, two main strategies were investigated: directly detecting oxygen levels in tumors and monitoring the hypoxia-assisted reduced microenvironment. We believe that hypoxia as a tumor-specific microenvironment can be a breakthrough in the clinical treatment of tumors.
Similar content being viewed by others
References
Albini, A., and Sporn, M.B. (2007). The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7, 139–147.
Anastasiadis, A.G., Stisser, B.C., Ghafar, M.A., Burchardt, M., and Buttyan, R. (2002). Tumor hypoxia and the progression of prostate cancer. Curr Urol Rep 3, 222–228.
Balkwill, F.R., Capasso, M., and Hagemann, T. (2012). The tumor microenvironment at a glance. J Cell Sci 125, 5591–5596.
Banchereau, J., and Palucka, A.K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5, 296–306.
Bastiaens, P., and Squire, A. (1999). Fluorescence lifetime imaging microscopy: spatial resolution of biochemical processes in the cell. Trends Cell Biol 9, 48–52.
Becker, W. (2012). Fluorescence lifetime imaging—techniques and applications. J Microsc 247, 119–136.
Berezin, M.Y., and Achilefu, S. (2010). Fluorescence lifetime measurements and biological imaging. Chem Rev 110, 2641–2684.
Bergman, I. (1968). Rapid-response atmospheric oxygen monitor based on fluorescence quenching. Nature 218, 396.
Brown, J.M., and Giaccia, A.J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408–1416.
Brown, J.M., and Wilson, W.R. (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4, 437–447.
Cao, P., Deng, Z., Wan, M., Huang, W., Cramer, S.D., Xu, J., Lei, M., and Sui, G. (2010). MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β. Mol Cancer 9, 108.
Cerqueira, B.B.S., Lasham, A., Shelling, A.N., and Al-Kassas, R. (2015). Nanoparticle therapeutics: technologies and methods for overcoming cancer. Eur J Pharm Biopharm 97, 140–151.
Chen, S.H., Forrester, W., and Lahav, G. (2016). Schedule-dependent interaction between anticancer treatments. Science 351, 1204–1208.
Chevalier, A., Zhang, Y., Khdour, O.M., Kaye, J.B., and Hecht, S.M. (2016). Mitochondrial nitroreductase activity enables selective imaging and therapeutic targeting. J Am Chem Soc 138, 12009–12012.
Dai, Y., Xu, C., Sun, X., and Chen, X. (2017). Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev 46, 3830–3852.
Davis, M.E., Chen, Z.G., and Shin, D.M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7, 771–782.
Denko, N.C. (2008). Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8, 705–713.
Denko, N.C., Fontana, L.A., Hudson, K.M., Sutphin, P.D., Raychaudhuri, S., Altman, R., and Giaccia, A.J. (2003). Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22, 5907–5914.
Denny, W.A. (2010). Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncology 6, 419–428.
Dong, J., Xu, J., Wang, X., and **, B. (2016). Influence of the interaction between long noncoding RNAs and hypoxia on tumorigenesis. Tumor Biol 37, 1379–1385.
Ding, Y., Wang, R., Zhang, J., Zhao, A., Lu, H., Li, W., Wang, C., and Yuan, X. (2019). Potential regulation mechanisms of P-gp in the bloodbrain barrier in hypoxia. Curr Pharm Des 25, 1041–1051.
Erler, J.T., Bennewith, K.L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q. T., Chi, J.T.A., Jeffrey, S.S., and Giaccia, A.J. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222–1226.
Finikova, O.S., Lebedev, A.Y., Aprelev, A., Troxler, T., Gao, F., Garnacho, C., Muro, S., Hochstrasser, R.M., and Vinogradov, S.A. (2008). Oxygen microscopy by two-photon-excited phosphorescence. ChemPhysChem 9, 1673–1679.
Gao, M., Yu, F., Lv, C., Choo, J., and Chen, L. (2017). Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy. Chem Soc Rev 46, 2237–2271.
Gao, X., Cui, Y., Levenson, R.M., Chung, L.W.K., and Nie, S. (2004). In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22, 969–976.
Gilkes, D.M., Semenza, G.L., and Wirtz, D. (2014). Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 14, 430–439.
Hida, K., Ohga, N., Akiyama, K., Maishi, N., and Hida, Y. (2013). Heterogeneity of tumor endothelial cells. Cancer Sci 104, 1391–1395.
Höckel, M., Schlenger, K., Knoop, C., and Vaupel, P. (1991). Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 51, 6098–6102.
Horsman, M.R., Mortensen, L.S., Petersen, J.B., Busk, M., and Overgaard, J. (2012). Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9, 674–687.
Junttila, M.R., and de Sauvage, F.J. (2013). Influence of tumour microenvironment heterogeneity on therapeutic response. Nature 501, 346–354.
Khawar, I.A., Kim, J.H., and Kuh, H.J. (2015). Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release 201, 78–89.
Kiyose, K., Hanaoka, K., Oushiki, D., Nakamura, T., Kajimura, M., Suematsu, M., Nishimatsu, H., Yamane, T., Terai, T., Hirata, Y., et al. (2010). Hypoxia-sensitive fluorescent probes for in vivo real-time fluorescence imaging of acute ischemia. J Am Chem Soc 132, 15846–15848.
Kizaka-Kondoh, S., Inoue, M., Harada, H., and Hiraoka, M. (2003). Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94, 1021–1028.
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., and Storm, G. (2016). Cancer nanomedicine: is targeting our target? Nat Rev Mater 1, 16069.
Leithner, K., Wohlkoenig, C., Stacher, E., Lindenmann, J., Hofmann, N.A., Gallé, B., Guelly, C., Quehenberger, F., Stiegler, P., Smolle-Jüttner, F. M., et al. (2014). Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model—role of tumor stroma cells. BMC Cancer 14, 40.
Li, B., Gu, Z., Kurniawan, N., Chen, W., and Xu, Z.P. (2017). Manganesebased layered double hydroxide nanoparticles as a T1-MRI contrast agent with ultrasensitive pH response and high relaxivity. Adv Mater 29, 1700373.
Li, J., Fan, C., Pei, H., Shi, J., and Huang, Q. (2013a). Smart drug delivery nanocarriers with self-assembled DNA nanostructures. Adv Mater 25, 4386–4396.
Li, J., Yuan, Y., Zeng, G., Li, X., Yang, Z., Li, X., Jiang, R., Hu, W., Sun, P., Wang, Q., et al. (2016). A water-soluble conjugated polymer with azobenzol side chains based on “turn-on” effect for hypoxic cell imaging. Polym Chem 7, 6890–6894.
Li, Y., Sun, Y., Li, J., Su, Q., Yuan, W., Dai, Y., Han, C., Wang, Q., Feng, W., and Li, F. (2015). Ultrasensitive near-infrared fluorescenceenhanced probe for in vivo nitroreductase imaging. J Am Chem Soc 137, 6407–6416.
Li, Z., Gao, X., Shi, W., Li, X., and Ma, H. (2013b). 7-((5-Nitrothiophen-2- l)methoxy)-3H-phenoxazin-3-one as a spectroscopic off-on probe for highly sensitive and selective detection of nitroreductase. Chem Commun 49, 5859–5861.
Lin, Q., Bao, C., Yang, Y., Liang, Q., Zhang, D., Cheng, S., and Zhu, L. (2013). Highly discriminating photorelease of anticancer drugs based on hypoxia activatable phototrigger conjugated chitosan nanoparticles. Adv Mater 25, 1981–1986.
Liu, Y., Jiang, Y., Zhang, M., Tang, Z., He, M., and Bu, W. (2018a). Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors. Acc Chem Res 51, 2502–2511.
Liu, Y., Song, X., Wang, X., Wei, L., Liu, X., Yuan, S., and Lv, L. (2010). Effect of chronic intermittent hypoxia on biological behavior and hypoxia-associated gene expression in lung cancer cells. J Cell Biochem 111, 554–563.
Liu, Y., Teng, L., Chen, L., Ma, H., Liu, H.W., and Zhang, X.B. (2018b). Engineering of a near-infrared fluorescent probe for real-time simultaneous visualization of intracellular hypoxia and induced mitophagy. Chem Sci 9, 5347–5353.
Lloberas, N., Rama, I., Llaudó, I., Torras, J., Cerezo, G., Cassis, L., Franquesa, M., Merino, A., Benitez-Ribas, D., Cruzado, J.M., et al. (2013). Dendritic cells phenotype fitting under hypoxia or lipopolysaccharide; adenosine 5′-triphosphate-binding cassette transporters far beyond an efflux pump. Clin Exp Immunol 172, 444–454.
Lu, P., Weaver, V.M., and Werb, Z. (2012). The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196, 395–406.
Mao, Y., Keller, E.T., Garfield, D.H., Shen, K., and Wang, J. (2013). Stromal cells in tumor microenvironment and breast cancer. Cancer Metast Rev 32, 303–315.
Masson, N., and Ratcliffe, P.J. (2014). Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab 2, 3.
Mouw, J.K., Ou, G., and Weaver, V.M. (2014). Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol 15, 771–785.
Nagy, J.A., and Dvorak, H.F. (2012). Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metast 29, 657–662.
Nan, Y., Zhou, Q., Zhao, W., Lu, Y., and Xu, W. (2019). In vivo imaging of hypoxia generation stimulated by testosterone using a micelle-based near-infrared fluorescent probe. Senss Actuat B Chem 288, 543–551.
Okabe, K., Inada, N., Gota, C., Harada, Y., Funatsu, T., and Uchiyama, S. (2012). Intracellular temperature map** with a fluorescent polymeric thermometer and fluorescence lifetime imaging microscopy. Nat Commun 3, 705.
Papkovsky, D.B., and Dmitriev, R.I. (2013). Biological detection by optical oxygen sensing. Chem Soc Rev 42, 8700–8732.
Perche, F., Biswas, S., Wang, T., Zhu, L., and Torchilin, V.P. (2014). Hypoxia-targeted siRNA delivery. Angew Chem Int Ed 53, 3362–3366.
Piao, W., Tsuda, S., Tanaka, Y., Maeda, S., Liu, F., Takahashi, S., Kushida, Y., Komatsu, T., Ueno, T., Terai, T., et al. (2013). Development of azobased fluorescent probes to detect different levels of hypoxia. Angew Chem Int Ed 52, 13028–13032.
Pouysségur, J., Dayan, F., and Mazure, N.M. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437–443.
Quintero, M., Mackenzie, N., and Brennan, P.A. (2004). Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol 30, 465–468.
Rohwer, N., and Cramer, T. (2011). Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updates 14, 191–201.
Ryan, L.S., Gerberich, J., Cao, J., An, W., Jenkins, B.A., Mason, R.P., and Lippert, A.R. (2019). Kinetics-based measurement of hypoxia in living cells and animals using an acetoxymethyl ester chemiluminescent probe. ACS Sens 4, 1391–1398.
Rytelewski, M., Haryutyunan, K., Nwajei, F., Shanmugasundaram, M., Wspanialy, P., Zal, M.A., Chen, C.H., El Khatib, M., Plunkett, S., Vinogradov, S.A., et al. (2019). Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors. J Immunother Cancer 7, 78.
Sharma, A., Arambula, J.F., Koo, S., Kumar, R., Singh, H., Sessler, J.L., and Kim, J.S. (2019). Hypoxia-targeted drug delivery. Chem Soc Rev 48, 771–813.
Sharma, R., and Chen, C.J. (2009). Newer nanoparticles in hyperthermia treatment and thermometry. J Nanopart Res 11, 671–689.
Sun, C.Y., Shen, S., Xu, C.F., Li, H.J., Liu, Y., Cao, Z.T., Yang, X.Z., **a, J. X., and Wang, J. (2015). Tumor acidity-sensitive polymeric vector for active targeted siRNA delivery. J Am Chem Soc 137, 15217–15224.
Takasawa, M., Moustafa, R.R., and Baron, J.C. (2008). Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke 39, 1629–1637.
Thambi, T., Deepagan, V.G., Yoon, H.Y., Han, H.S., Kim, S.H., Son, S., Jo, D.G., Ahn, C.H., Suh, Y.D., Kim, K., et al. (2014). Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials 35, 1735–1743.
Turley, S.J., Cremasco, V., and Astarita, J.L. (2015). Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 15, 669–682.
Ueno, T., Urano, Y., Setsukinai, K.I., Takakusa, H., Kojima, H., Kikuchi, K., Ohkubo, K., Fukuzumi, S., and Nagano, T. (2004). Rational principles for modulating fluorescence properties of fluorescein. J Am Chem Soc 126, 14079–14085.
VanHook, A.M. (2017). Hypoxia-induced plasticity in cancer cell migration. Sci Signal 10, eaan0467.
Vaupel, P., and Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast Rev 26, 225–239.
Vaupel, P., Schlenger, K., Knoop, C., and Höckel, M. (1991). Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51, 3316–3322.
Wang, G.L., Jiang, B.H., Rue, E.A., and Semenza, G.L. (1995). Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.. Proc Natl Acad Sci USA 92, 5510–5514.
Wang, S., Gu, K., Guo, Z., Yan, C., Yang, T., Chen, Z., Tian, H., and Zhu, W.H. (2019). Self-assembly of a monochromophore-based polymer enables unprecedented ratiometric tracing of hypoxia. Adv Mater 31, 1805735.
Weissleder, R. (2001). A clearer vision for in vivo imaging. Nat Biotechnol 19, 316–317.
Yu, J., Zhang, Y., Hu, X., Wright, G., and Gu, Z. (2016). Hypoxia-sensitive materials for biomedical applications. Ann Biomed Eng 44, 1931–1945.
Zeng, Y., Zhang, S., Jia, M., Liu, Y., Shang, J., Guo, Y., Xu, J., and Wu, D. (2013). Hypoxia-sensitive bis(2-(2′-benzothienyl)pyridinato-N,C3′) iridium[poly(n-butyl cyanoacrylate]/chitosan nanoparticles and their phosphorescence tumor imaging in vitro and in vivo. Nanoscale 5, 12633–12644.
Zhang, K.Y., Gao, P., Sun, G., Zhang, T., Li, X., Liu, S., Zhao, Q., Lo, K.K. W., and Huang, W. (2018a). Dual-phosphorescent iridium(III) complexes extending oxygen sensing from hypoxia to hyperoxia. J Am Chem Soc 140, 7827–7834.
Zhang, Q., Chen, J., Ma, M., Wang, H., and Chen, H. (2018b). A bioenvironment-responsive versatile nanoplatform enabling rapid clearance and effective tumor homing for oxygen-enhanced radiotherapy. Chem Mater 30, 5412–5421.
Zhao, X., Li, F., Li, Y., Wang, H., Ren, H., Chen, J., Nie, G., and Hao, J. (2015). Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials 46, 13–25.
Zhao, Y., Liu, L., Luo, T., Hong, L., Peng, X., Austin, R.H., and Qu, J. (2018). A platinum-porphine/poly(perfluoroether) film oxygen tension sensor for noninvasive local monitoring of cellular oxygen metabolism using phosphorescence lifetime imaging. Senss Actuat B Chem 269, 88–95.
Acknowledgements
This work was supported by the China Postdoctoral Science Foundation (2019M651598), the National Natural Science Foundation of China (51772316), and the Key Program for Basic Research of Shanghai (19JC1415600).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The author(s) declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Xue, F., Chen, J. & Chen, H. Design strategy of optical probes for tumor hypoxia imaging. Sci. China Life Sci. 63, 1786–1797 (2020). https://doi.org/10.1007/s11427-019-1569-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-019-1569-4